Novel Hantzsch 1,4-dihydropyridines to study the structure-function relationships of calcium channels and photoinduced relaxation

Drug Development Research

Volumn 42, Issue 3-4, 1997, Pages 120-130

  Iqbal, Nadeem ^a   Triggle, Christopher R ^b   Knaus, Edward E ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

1,4 dihydropyridines; Calcium channel antagonists

Indexed keywords

1,4 DIHYDROPYRIDINE DERIVATIVE; CALCIUM CHANNEL; NIFEDIPINE;

ANIMAL TISSUE; ARTICLE; CALCIUM ANTAGONISM; CONTROLLED STUDY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; GUINEA PIG; ILEUM; IN VITRO STUDY; INFRARED SPECTROPHOTOMETRY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; REACTION ANALYSIS; SMOOTH MUSCLE CONTRACTION; STRUCTURE ACTIVITY RELATION; ULTRAVIOLET SPECTROPHOTOMETRY;

EID: 0031393980     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(199711/12)42:3/4<120::AID-DDR3>3.0.CO;2-S     Document Type: Article

References (43)

1. 2+ channel agonists and antagonists potentiate ultraviolet light-induced relaxation through cyclic GMP formation in porcine coronay artery. J Cardiovasc Pharmacol 23:785-791.
2. Baxter AJ, Dixon J, Inu F, Manners CN, Teague SJ (1993): Discovery and synthesis of methyl 2,5-dimethyl-4-[2-(phenylmethyl)benzoyl]-1H-pyrrole-3-carboxylate (FPL 64176) and analogues: The first example of a new class of calcium channel activator. J Med Chem 36:2739-2744.
3. 2+ channels. Trends Pharmacol Sci 9:257-261.
4. Beyer T, Gjorstrup P, Ravens U (1985): Comparison of the cardiac effect of the derivative H 160/51 with those of the 'Ca-agonist' Bay K 8644. Naunyn Schmiedebergs Arch Pharmacol 330:R34.
5. Chang KC, Kim YS, Lu SY (1993): Is the L-arginine/NO pathway involved in photorelaxation in rat aorta? Pharmacol Commun 4:67-75.
6. Dagnino L, Li-Kwong-Ken MC, Wolowyk MW, Wynn H, Triggle CR, Knaus EE (1986): Synthesis and calcium channel antagonist activity of dialkyl 1,4-dihydro-2,6-dimethyl-4-(pyridinyl)-3,5-pyridinedicarboxylates. J Med Chem 29:2524-2529.
7. Dagnino L, Li-Kwong-Ken MC, Wynn H, Wolowyk MW, Triggle CR, Knaus EE (1987): Synthesis and calcium channel antagonist activity of dialkyl 4-(dihydropyridyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboylates. J Med Chem 30:640-646.
8. Davis AM, Gensmantel NP, Johansson E, Marriott DP (1994): The use of the GRID program in the 3-D QSAR analysis of a series of calcium channel agonists. J Med Chem 37:963-972.
9. Entwistle ID, Gilkerson T, Johnstone RAW, Telford RP (1978): Rapid catalytic transfer reduction of aromatic nitro compounds to hydroxylamines. Tetrahedron 34:213-215 (and ref. therein).
10. Erhardt PW (1987): In search of the digitalis replacement. J Med Chem 30:231-237.
11. Erne P, Burgesser E, Buhler FR, Duback B, Kuhnis H, Meier M, Rogg H (1984): Enhancement of calcium flux in human platelets by CGP 28392, a novel dihydropyridine. Biochem Biophys Res Commun 118:842-847.
12. Fiakpui CY, Philips OA, Murthy KSP, Knaus EE (1993): Synthesis and anticonvulsant activity of 1,3-dihydro-5-phenyl-2H-pyrido[3,4-e]-1,4-diazepin-2-ones. Drug Design Discov 10:45-55.
13. Gjorstrup P, Harding H, Isaksson R, Westerlund C (1986): Enantiomers of the dihydropyridine derivative H 160/51 show opposite effects of stimulation and inhibition. Eur J Pharmacol 122:357-361.
14. Goldenberg IF, Cohn JN (1987): New inotropic drugs for heart failure. JAMA 258:493-196.
15. Golenhofen K, Finger K, Foster B, Mandrek K, Noak T (1990): Light induced relaxation of smooth muscle after treatment with Bay K 8644 is related to release of nitric oxide. In Sperolakis N, Wood J (eds): Frontiers in Smooth Muscle Research. New York: Wiley-Liss, pp 595-604.
16. Gorlitzer K, Schmidt E (1991): Benzohydroxamic acids from nifedipine and the corresponding 1,2-dihydropyridine compound. Arch Pharm 324:101-104.
17. Gross R, Kayser M, Schramm M, Taniel R, Thomas G (1985): Cardiovascular effects of the calcium-agonistic dihydropyridine Bay K 8644 in conscious dogs. Arch Int Pharmacodyn Ther 277: 203-216.
18. Hayase N, Itagaki Y-I, Ogawa S, Akutsu S, Inagaki S-I, Abiko Y (1994): Newly discovered photodegradation products of nifedipine in hospital prescriptions. J Pharm Sci 83:532-538 (and ref. therein).
19. Hazard R, Hurvois JP, Moinet C, Tallec A, Burgot JL, Eon-Burgot G (1991): On the electrochemcial behaviour of nifedipine and related compounds: Instability of the reduction products in protic media. Electrochimica Acta 36:1135-1141.
20. Hof RF, Ruegg UT, Hof A, Vogel A (1985): Stereoselectivity at the calcium channel: Opposite action of the enantiomers of a 1,4-dihydropyridine. J Cardiovasc Pharmacol 7:689-693.
21. Holland DR, Wikel JH, Kaufman RE, Smallwood JK, Zimmerman KM, Utterback BG, Turk JA, Steinbert MI (1989): LY249933: A cardioselective 1,4-dihydropyridine with positive intropic activity. J Cardiovasc Pharmacol 14:483-491.
22. Hurd CD, Nilson ME (1955): Aliphatic nitro ketones. J Org Chem 20:927-936.
23. Jacobson HI, Griffin MJ, Preis S, Jensen EV (1957): Phosphonic acids. IV. Preparation and reactions of β-ketophosphonate and enol phosphate esters. J Am Chem Soc 79:2608-2612.
24. 2+ channel antagonists. J Med Chem 26:775-785.
25. Loev B, Goodman MM, Snader KM, Tedeschi R, Macko E (1974): "Hantzsch-type" dihydropyridine hypotensive agents. J Med Chem 17:956-965.
26. Lovren F, O'Neill SK, Bieger D, Iqbal N, Knans EE, Triggle CR (1996): Nitric oxide, a possible mediator of 1,4-dihydropyridine-induced photorelaxation of vascular smooth muscle. Br J Pharmacol 118:879-884.
27. Mager P, Coburn RA, Solo RA, Triggle DJ, Rothe H (1992): QSAR, Diagnostic statistics and molecular modeling of 1,4-dihydropyridine calcium channel antagonists: A difficult road ahead. Drug Des Discov 8:273-289.
28. Marks GS, McLaughlin BE, Brown LB, Beaton DE, Booth BP, Nakatsu K, Brien JF (1991): Interaction of glyceryl trinitrate and sodium nitroprusside with bovine pulmonary vein homogenate and nitric oxide formation. Can J Physiol Pharmacol 69:889-892.
29. Matsunaga K, Furchgott RF (1989): Interaction of light and sodium nitrite in producing relaxation of rabbit aorta. J Pharmacol Exp Ther 248:687-695.
30. Mikkelsen E, Kazda S (1985): Effects of light and Bay K 8644, a new 1,4-dihydropyridine on mechanical responses of rat thoracic aorta. Acta Pharmacol Toxicol 56:126-132.
31. Noack E, Feelisch M (1991): Mechanisms of nitrovasodilator bioactivation. Basic Res Cardiol 2:37-50.
32. Preuss KC, Cheung NL, Brooks HL, Warltier DC (1984): Cardiovascular effects of the nifedipine analog, CGP 28392, in conscious dog. J Cardiovasc Pharmacol 6:949-953.
33. Preuss KC, Brooks HL, Gross GJ, Warltier DC (1985): Positive inotropic actions of the calcium channel stimulator, Bay K 8644, in awake, unsedated dogs. Basic Res Cardiol 80:326-332.
34. 2+ channels. Nature 303:535-537.
35. Sunkel CE, Fan de Casa-Juana M, Santos L, Garcia AG, Artalejo CR, Villarroya M, Gonsalez-Morales MA, Lopez MG, Cillero J, Alonso S, Priego JG (1992): Synthesis of 3-[2,3-dihydro-1,1,3-trioxo-1,2-benzisothiazol-2-yl)alkyl]-1,4-dihydropyridine- 3,5-dicarboxylate derivatives as calcium channel modulators. J Med Chem 35:2407-2414.
36. Takeda Y (1993): Single channel analysis of calcium ion channel-agonistic action of dihydropyridine derivatives. Voltage-dependent effects of YC-170 and Bay K 8644. Hakkaido Igaku Zasshi 68:557-569.
37. Takenaka T, Maeno H (1983): A new vasoconstrictor 1,4-dihydropyridine derivative, YC-170. Jpn J Pharmacol 32:139.
38. Timmis AD, Smyth P, Kenny JF, Campbell S, Jewitt DE (1984): Effects of vasodilator treatment with felodipine on haemodynamic responses to treadmill exercise in congestive heart failure. Br Heart J 52:314-320.
39. Triggle CR, Bieger D (1990): Can dihydropyridines enhance photorelaxation of smooth muscle by calcium independent mechanisms? Proc West Pharmacol 33:227-232.
40. Triggle CR, O'Neill SK, Bieger D (1991): NO: Role in dihydropyridine enhance photorelaxation of vascular smooth muscle. In Mulvaney MJ, Aalkjaer C, Heagerty AM, Nyborg NCB, Strandgaard S (eds): Resistance Arteries, Structures and Function. Amsterdam: Elsevier, pp 233-237.
41. Vo D, Wolowyk MW, Knaus EE (1992): Synthesis and cardioselective β-adrenergic antagonist activity of quinolyloxypropanolamines. Drug Des Discov 9:69-78.
42. Vo D, Matowe WC, Ramesh M, Iqbal N, Wolowyk MW, Howlett SE, Knaus EE (1995): Synthesis, calcium channel agonist-antagonist modulation activities, and voltage-clamp studies of isopropyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-pyridinylpyridine-5-carboxylate racemates and enantiomers. J Med Chem 38:2851-2859.
43. Wood WW, Wilkin JA (1992): A convenient synthesis of aryl nitroso compounds. Syn Commun 22:1683-1686.